Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.
Clarke JM, Simon GR, Mamdani H, Gu L, Herndon JE 2nd, Stinchcombe TE, Ready N, Crawford J, Sonpavde G, Balevic S, Nixon AB, Campa M, Gottlin EB, Li H, Saxena R, He YW, Antonia S, Patz EF Jr.
Clarke JM, et al. Among authors: gu l.
Nat Commun. 2025 Jan 2;16(1):93. doi: 10.1038/s41467-024-55092-2.
Nat Commun. 2025.
PMID: 39747856
Clinical Trial.